Business Context and Reporting Period
This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of July 2018, specifically dated July 9, 2018. The registrant is a foreign private issuer incorporated in Belgium, with its principal executive office in Mechelen. The filing serves to incorporate a press release (Exhibit 99.1) into the company's existing Registration Statements on Forms F-3 and S-8.
Financial Metrics
The filing text does not provide specific financial data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity within this document. The filing is a procedural submission to distribute a press release rather than a financial report.
Material Changes
The document does not detail material changes in financial position or operations compared to prior periods. The primary content is the announcement of a press release issued on July 9, 2018, the specific details of which are contained in the attached Exhibit 99.1 and are not summarized in the body of this Form 6-K.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, risk factors, or contingencies. It references a press release but does not reproduce its content, except to note that a quote by Dr. Piet Wigerinck is excluded from incorporation by reference.
Key Facts for Investor Verification
- Verify the actual company name: The filing is for Galapagos NV, despite metadata suggesting Lakefront Biotherapeutics NV.
- Review Exhibit 99.1 (the press release dated July 9, 2018) for the substantive news, as the Form 6-K body contains no operational or financial details.
- Note that the filing incorporates the press release into active registration statements (Forms F-3 and S-8) for potential capital raising.
- Confirm that no financial metrics are disclosed in this specific filing; investors must refer to the company's most recent Form 20-F or quarterly reports for financial data.